Here’s some more of what was said
“I see people who are developing products who are making claims that marijuana has antitumor effects in the setting of cancer,” Gottlieb told Congress. “It’s a much broader question about where our responsibility is to step into this.”
He also said, “We’ll have some answers to this question very soon because I think we do bear some responsibility to start to address these questions.”
While Gottlieb didn’t offer any specifics, it’s clear that the FDA is considering how to handle marijuana products and their various health claims.
The problem is there isn’t an abundance of research on marijuana for the FDA to draw upon. There actually are studies that showed cannabis use both slowed the progression of cancer and even reduced tumors in some cases. But since the federal government continues to classify marijuana as a Schedule I narcotic, studies are rare and there isn’t a ton of evidence to definitively prove what the drug can or cannot do.